Physician profile
Ghulam Dastgir
NPI 1215297338
$5,021.45
in general payments reported to CMS, 2019-2025
22 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $244 · 2021: $687 · 2022: $475 · 2023: $382 · 2024: $2,515 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,826 · Food and Beverage: $1,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,825.74 |
| Food and Beverage | $1,633.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,016.97 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $464.53 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $423.22 | 2021-2025 | |
| Oyster Point Pharma, INC. | $289.81 | 2022-2025 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $194.73 | 2021-2022 | |
| Abbvie INC. | $183.89 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Harrow Eye, LLC | $182.44 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $179.75 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Alcon Vision LLC | $156.65 | 2022-2025 | Rocklatan, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $144.16 | 2019-2021 | |
| Amgen INC. | $98.31 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $97.99 | 2022 | |
| Akorn Operating Company LLC | $93.77 | 2021 | |
| Shire North American Group INC | $86.74 | 2019 | |
| Horizon Therapeutics Plc | $82.63 | 2022-2023 | Tepezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $82.25 | 2023-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $60.88 | 2019-2020 | |
| Sight Sciences, INC. | $48.71 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $44.17 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $38.03 | 2021 | |
| Allergan, INC. | $33.27 | 2020 | |
| Dompe US, INC. | $18.55 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghulam Dastgir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.